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CHAPTER I 
INTRODUCTION 
Chemotherapy is a formidable weapon in man's arsenal 
for his continuous warfare against cancer. Before a 
compound can be used clinically, however, it must with-
stand a battery of tests against several animal tumor 
systems and against cell cultures. Volumes of data 
accumulated during the course of such p~eliminary screen-
ings could be successfully utilized in drug design. Drug 
design can play a very important role not only in reducing 
the amount of work involved in modifYing a successful 
therapeutic agent for increased potency but also in propa-
gating new 4rugs. 
Quinones are known to possess some antitumor 
activity17 • They have demonstrated other types of biolo-
gical activity as we113• Quantitative structure-activity 
relationships constitute a major facet of drug design, 
Hansch-type multiple regression analysis being the fore-
most22. Discriminant analysis, a relatively new qualita-
tive structure-activity method, has been applied to a few 
systems with success36• 
The de ~ method developed by Free and Wilsontg 
could be useful in assigning additivity constants to 
1 
.2 
structural features of compounds belonging to a aeries and 
thereby evaluating the contributions of various substi-
tuents to the biological activity. 
The purpose of this work was, hence, to prepare 
several benzoquinone analogues, measure their antitumor 
activities against ascitic Sarcoma 180 tumor system in 
Swiss mice and apply statistical methods to the data thus 
obtained with a view to evaluating the potential of these 
compounds as antitumor agents and putting in perspective 
the usefulness of the structure-activit.y methods. 
CHAPTER II 
HISTORICAL 
While it may be naive to expect a miracle drug or a 
magic bullet that will selectively destroy the malignant 
cell, chemotherapy remains a promising modality in the cur.e 
or at least, the control of cancer. Unavailability and/or 
prohibitive cost of other methods such as surgery and 
radiotherapy in many parts of .the world :have rendered 
chemotherapy increasingly important in the world health 
scene. Combination therapy, i.e., the application of 
chemotherapy along with the other modalities has come to 
be the most efficient approach against cancer. Excellent 
reviews depicting the role of drug therapy in the conti-
nuous combat against cancer can readily be found in 
recent literature5,6,12,51 
• 
The most extensive investigation of plant, microbial 
and synthetic drugs is operated by the Cancer Chemotherapy 
National Service Center of the National Cancer Institute, 
Bethesda, Maryland, USA. In addition, drug companies, 
specialized government agencies, co-operative agencies and 
academic institutions are contributing significantly to 
the development of anti-neoplastic agents. This has 
resulted in an enormous amount of data pertaining to 
4 
hundreds of thousands of potentially anticancer compounds. 
Unfortunately, this has resulted in fewer than 100 drugs 
which could be used clinically. 
Nonetheless, the seemingly endless search must go on. 
A realistic approach for drug design and development has 
been suggested by Alfred Burger7. Drug research has been 
termed a "lucky accident"9 and "the luck of the dra:w" 21 • 
Meanwhile, scientists worldwide are engaged in finding 
ways and means of rendering the drug research more of a 
systematic approach than a "hit or miss 11 proposition. 
Structure-activity relationships, attempting to correlate 
the effect of structure modifications on the .biological 
activities are an integral and essential part of such an 
attempt. They are especially effective in determining 
the most active compounds belonging to a series as well 
as in. unearthing new compounds po.tentially more active 
than the ones under investigation. 
Multiple-parameter regression analysis is the fore-
most amongst the quantitative structure-activity studies 
and is popularly known as the Hansch method after its 
illustrious sire. This involves preparation of several 
compounds with a parent structure and several substituents 
and evaluation of their biological activities. Biological 
activity should be expressible in the form of a molar 
concentration of compound producing a standard response 
in a constant time interval. Various properties of the 
substituents can be quantified in terms of substituent 
5 
constants: Hammett-type 6' constants for electronic proper-
ties 20, Hansch-type 7\ constants for lipophilic! ty-
hydrophobici ty23 •26 , Swain and Lupton-type 5 3 ~ and R 
constants for field and.resonance effects, and molar 
refraction for general 11 steric bulk". Numerical values of 
these constants for over 200 substituents have been 
listed24• A recent article includes values for 48 
additional substituents25. 
Typically the biological response, log (1/C), to the 
drug can then be expressed as the following equation: 
log (1/C) = k1o+ k27T+ k:31\.2..+ k4MR + k5'fC + k6R + k7 (1) 
where Cis the concentration or dose of:a drug that will 
produce a given response. By the use of a multiple 
regression analysis all the constants can be evaluated; 
the equation (1) is called a structure-activity-
relationship (SAR). A typical example will be toxicities 
---. ~·.. ' 
of (2-bromoethylthio)ben~enes a~ainst eel! o! Tetranychus 
telarius (L) 27. . 
-log w5o 
(n = 8; s 
where 
Q~s:.cH2c~2~ ·· X . . ; . 
. ,, 
= -2. 18f'(.z..+ 1 • 6917"- 1 • 45 d" + 4. 38 
= 0.164; r = 0.968) 
LC 50 = lethal concentration, 5~ 
n = number of compounds 
s = standard deviation 
r = multiple regression coefficient. 
(2) 
6 
It is then conceivable that the 10 50 of a compound bearing 
a new substituent could be calculated by substituting· the 
values for the various parameters in equation (2). A 
comprehensive treatise is available on this subject55• 
Before one could arrive at a standard response, it 
is ne~essary to have detailed biological information in 
the form of dose-response curves. This is not generally 
accesible to medicinal chemists from the vast amount of 
. 
screening data present in the literature. Even when dose-
response curves are available or have been determined, 
the estimated concentration suffers from inherent inter-
polation errors. There is yet another statistical tool 
available which removes the necessity of a specific con-
centration value. This method, known as discriminant 
analysis, requires only that compounds belonging to a 
chemical series be classified into two or more distinct 
groups based on some form of biological activity34,35. 
Instances where disciminant analyses have been used 
successfully in structure-activity-relationship studies 
are scarceo Martin et al.36 have used it to study the 
relationship between structure and the inhibition of 
monoamine oxidase by aminotetralins and aminoindana. The 
usefulness of disciminant analysis in the study of 
·synthetic antitumor compounds has been demonstrated by 
Hodenett and co-workers28 ' 29' 45. 
Once again, a series of compounds with a parent 
structure and various substituents has to be prepared and 
7 
the biological activities evaluated. It is then necessary 
to classify the compounds into two or more groups on some 
biological basis. Substituent properties are expressed in 
a manner similar to that used in the Hansch method and 
subjected to discriminant analysis. Results of such an 
analysis, usually in the form of discriminant functions, 
will indicate which of the structural variations are most 
important in determining whether or not a compound is 
active. 
An example is found in the case of fifteen 
naphthoquinones and their activities against ascitic 
sarcoma 180 tumor sy~tem in Swiss mice45. The classifica-
tion functions obtained for moderately active compounds: 
~ 
-28.0(7.60)71+ 9.81(5.30)MR + 9.44(3.70) n- 455(3.57)Ei 
-71.1 
for active compounds: 
'2-
-18.6(7.60)7T+ 7.30(5.30)MR + 6.30(3.70) 11- 392(3.57)Ei 
-52.8 (3) 
whererr is the hydrophobic parameter developed by Hansch, 
MR is the molar refractivity and Ei is the polarographic 
half-wave potential. The numbers given in parentheses are 
F-values with the degrees of freedom 1,10 for a given 
variable. By comparing these values with the standard F 
distribution, one can determine at what level of statisti-
cal significance that variable alone can differentiate 
between the two groups. Only if this significance level 
is above a particular value is the variable in question 
8 
allowed to enter the classification function. Each of the 
classification functions describes the cases belonging to 
that group. A discriminant function capable of assigning 
a compound to either group is readily derived by taking 
the difference between the corresponding coefficients. 
Such a function placed all the fifteen compounds into 
their proper groups at a confidence level of more than 
95% (F = 4.38)F4, 10 , 0 •95 = 3.48). The signs of the 
coefficients indicate whether a particular parameter 
should be increased or decreased to obtain enhanced biolo-
gical activity. By substituting numerical values for the 
substituent parameters for a new compound in the discri-
minant function, one can evaluate the probability tha.t 
the compound will belong to either group. 
The Free-Wilson additivity model does not use para-
meters to describe the various physiocochemical 
properties of substituents18• An excellent review 
describing the method and comparing it to the Hansch 
method is available14. According to the Free-Wilson 
method, a series of ~ ~ constants is derived using 
only the biological activities of compounds and the 
following basic assumption: a particular substituent will 
play a constant role in determining the over-all biologi-
cal activity of the molecule. It may contribute to, or 
detract from, the over-all biological activity, but it 
must always play the same role. 
This basic assumption is checked by the statistical 
parameters which result from the solution of a matrix, 
which expresses the above assumption in the .form of the 
fo11owing equation for each compound, 
9 
Biological activity =J-L +z.!GiXi (4) 
where~is the average biological activity and GiXi 
represents the contribution of the ith group at the ith 
position to the biological activity. In constructing 
the matrix, X takes the value of 0 or 1 to indicate the 
absence or the presence of the group in a given molecule. 
The matrix thus represents a series of equations in 
multiple unknowns, one equation per compound. The solu-
tion of the least square matrix yields the values for·7 tn 
~ B2!2 substituent constants for every substituent at 
each position. 
An example of the successful application of this 
method is presented by Free and Wilson18 using the!!! 
vitro inhibitory potencies of ten Q,isubstituted against 
Staphylococcus aureus. The analogs included the following: 
N!CH3}2 
OH 
where R = H or CH3; X = Br, Cl, or N02; and Y = 
or cH3coNH. 
Eighteen compounds are possible with these structural 
10 
variations but only ten were tested. The matrix used is 
shown in Table I, and the results are shown in Table II. 
Th~ model accounted for 90.6% of the total variation of 
the biological activity. The results suggest that the 
best compound in the series would have R = H, X = Cl and 
Y = NH2• The estimated biological activity would be 443 
and the actual response was 525. The discrepancy might 
be due to biological variation in the 1a vitro procedure 
or the presence of a nonadditive component in the series, 
since the model accounts for 90~ of the total variation, 
the latter possibility can be discounted. 
Biological functions of quinones have been recogniaed 
for a long time'7• Antitumor activities of naturally 
occurring and synthetic quinones have been catalogued by 
Driscoll et a1. 17• Extensive work on the antitumor 
characteristics of certain synthetics has been done by 
Sartorelli and co-workers'1• 32 • 33 and Drisco1113• 17 • Some 
of the naturally occuring quinones like anthracyclines, 
mitomycins, streptonigrin and lapachol have also exhibited 
antineoplastic activity 17• 19• 47 •49. Some of these are 
shown in Figure 1. They are known to possess anti-
bacterial, antifungal and enzyme inhibition properties 
as we113• 
About two hundred quinonoid compounds have been 
.screened by NCI for antitumor activities, but, nitrogen 
analogs of quinones have not been so extensively studied. 
Several benzoquinones analogs have been studied and their 
TABLE I 
· BIOLOGICAL ACTIVITY OF TEN 
TETRACYCLINES 
--~------.--22!!!122!!!!g_!{t~!!~!!'!£~~!2!!----------- Bio-
R X y logical 
------
----------- -----------------~-- Activity H CH3 N02 Cl Br N02 NH2 CH3CONH 
1 1 1 60 
1 1 1 21 
1 1 1 15 
1 1 1 525 
1 1 1 320 
1 1 1 275 
1 1 1 160 
1 1 1 15 
1 1 1 140 
1 1 1 75 
TABLE II 
CONTRIBUTION OF STRUCTURAL CHAN~ES 
TO ACTIVIT-:Y OF TETRACYCLINES 
Side Chain Positions 
----------------------------------------------------------R . X Y 
--------------- -------------- ---------------------
a H 75 b Cl 84 c t{H2 123 
a CH3 -112 b Br . -16 c C,H3CONH- 18 
b N02 -26 c N02 -218 
aThe solution includes these restrietions: -6a tt ·-+. 
4a CH3 = 0; 2b Cl + 4b Br + 4b N02 = 0; and 5c ~H2 
+ 2c CH3CONH-- + 3c N02 = o. The over-all average was 
161. 
0 
0 
MeO 0 
Adriamycin, R = OH 
COOH 
0~ 
Streptomycin 
~N 
Daunomycin, R = H 
0 
Mytomycin, R = H 
Porfiromycin, R = CH3 
1.3 
Figure 1. Some Naturally Occurring Quinones Showing 
Potential Antitumor Activity 
14 
biological activities evaluated4•28• The mechanism of 
action is apparently different for each mode of activity 
complicated by the difference in structures. However, the 
redox capacity of the structurally different quinones 
seems to be the key factor in electron transport and 
oxidative phosphorylation. processes37. 
CHAPTER III 
EXPERIMENTAL 
Preparation of Compounds . 
The system of compounds chosen for this study is 
where Y = Cl or Br, and X = H, Cl, CH3, N02 or so3Na. The 
IUPAC name for these is 2-substituted-N,N'-dihalo-2,5-
cyclohexadien-1,4-diimines. For convenience's sake, these 
are referred to as 2-substituted-N,N'-dihalo-1,4-benzo-
quinonediimines~- In Table:III, these compounds a±-e 
assigned numbers by which they are designated throughout 
the thesis. 
Compounds 2, 3, 4, a, 9, and 10 were stabilized by 
adding buffering agents such as Na2HP04, K2HP04, or AcONa 
in order to maintain a pH of the compounds between 5-852 • 
Compounds 4 and 5 were mixed with various arylamines to 
yield differing shades of color and were used for .• ing 
or printing polypropylene fibera43. Melting points have 
been reported only for compounds 1, 2, and 342 • Melting 
15 
Com]20Und 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
.* The 
designate 
No. 
TABLE III 
2-(SUBST+TUTED)-N,N'-UIHAL0-1,4-
BEN Z OQ-qiN ON EDI H1I NES 
*. y 
Cl 
Cl 
Cl 
Cl 
Cl 
Cl 
Br 
Br 
Br 
Br 
Br 
Br 
/y 
N 
compound numbers given in this table are 
the compounds throughout this thesis. 
16 
X 
H 
Cl 
CH3 
OCH3 
N02 
so3~a 
H 
Cl 
CH3 
OCH3 
N02 
so3Na 
used to 
17 
points reported for these are suspect because it is not 
clear whether the compounds were isolated, purified, and 
dried thoroughly. On the other hand, the melting.pointa 
reported in this thesis should be considered more reliable. 
Reasonable elemental analysis and proof of structures 
through spectral analysis render credibility to this claim. 
Detailed spectral and other chemical information on 
these compounds are provided herein for the first time. 
!1•N'-Dibromo-1,4-benzoguinonediimine8 
Bromine (32g, 0.2 mole) was dissolved in a solution 
of 16.7 g of sbdium hydroxide pellets (0.42 mole) in 500 
mL of water. This was chilled to 0°C and a solution of 
54 g of 1,4-phenylenediamine (0.05 mole) in 300 mL of water 
was added. The resulting reddish brown precipitate was 
filtered and washed repeatedly with generous portions 
of water. The precipitate was dried under vacuum. The 
crude product·was dissolved in 80 mL of warm benzene, 
shaken with anhydrous CaCl2 and filtered. Addition of 
60 mL of petroleum ether with chilling yielded 8.7 g of 
yellow solid, mp 99°C. The theoretical yield was 13.1 g. 
The melting point for this compound is not published. 
N,N'-Dibromo-2-methoxy-1,4-benzo-
guinonediimine 
Bromine (32g, 0.2 mole) was dissolved in a solution 
of 16.7 g (0.42 mole) of sodium hydroxide in 500 mL of 
water. 2-Methoxy-1,4-phenylenedlamine sulfate (11.8 g, 
0.05 mole) was dissolved in 900 mL of water. The hypo-
chlorite solution was stirred in a 2-liter beaker with 
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ice and the amine solution was added with stirring. The 
yellow solid which separated waa filtered out, washed with 
water and dried under vacuum. The crude product, upon 
recrystallization from 1:1 water-ethanol mixture, yielded 
4 g of purified product, mp . 87-89°C. Theoretical yi.eld 
was 14.6 ge No published melting point is available for 
this compound. 
Reduction of 2-methyl-4-nitroaniline 
2-Methyl-4-nitroaniline (30.4 g, 0.2 mole) was mixed 
with 118.6 g (1 mole) of mossy tin in a 250-mL flask. 
Ethanol (2 mL) was added to control the foaming. Con. 
hydrochloric acid (240 mL) and 300 mL of water were added 
and the reaction mixture was heated overnight with reflux. 
The almost colorless solution was decanted and kept in the 
refrigerator; The resulting glistening light-yellow plates 
were filtered and dried. The yield was 49.0 g. The crude 
2-methyl.;.1,4-phenylenediamine hexachlorostannate was :used 
in the oxidation step without further purification. 
Oxidation of 2-Methyl-1,4-phenylenediamfne 
hexachlorostannate with Clorox 
2-I-1:ethyl-1, 4-phenylenediamine hexachlorostarmate ( 22 
g, 0.05 mole) was dissolved in 800 mL of water. A pint 
of Clorox was stirred with ice in a 1-liter beaker and 
the amine-salt solution was added slowly with stirring. 
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A yellow precipitate formed; this was filtered out, washed 
with water and dried under vacuum. The crude 2-methyl-
N,N'-dichloro-1,4-benzoquinonediimine was recrystallized 
from absolute ethanol. The yield was 7.8 g; mp 184-185°0; 
published: 160°c 42• The theoretical yield was 9.45 g. 
Oxidation of 2-methyl-1 1 4-phenylenediamine 
£hlorostannate with hypobromite 
2-Methyl-1, 4--phenylenediamine· hexachlorostannate ( 11.4 
g, 0.025 mole) was dissolved in a solution of 8.4 g (0.21 
mole) of sodium hydroxide in 250 mL of water in a 1-liter 
beaker. To the cooled hypobromite solution waa added the 
amine-salt solution gradually and with stirring. The 
resulted flesh-colored precipitate was filtered, washed 
with water and dried under vacuum. The crude 2-methyl-
N,N'-dibromo-1,4-benzoquinonediimine was recrystallized 
from absolute ethanol. The yield was 4.8 g; mp 250°0. 
The theoretical yield was 6.90 g. The melting point for 
this compound. has not been reported. 
N,N'-Dichloro-1,4-benzoguinonediimine 
1,4-Phenylenediamine (5.4 g, 0.05 mole) was dissolved 
in 300 mL of water. A pint bottle of commercial bleach 
(Clorox, sodium hypochloride 5.25%) was stirred in a 1-
liter beaker witn ice. The amine solution was added 
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gradually with vigorous stirring. The resulting dirty 
yellow precipitate was filtered and rapidly washed with 
plenty of water and the solid was dried under vacuum. The 
crude product was recrystallized from absolute ethanol. 
The yield was 4.6 g; mp 127-129°0; published: 126-128°c42• 
The theoretical yield was 8.75 g. 
N,N'-Dibromo-2-chloro-1,4-benzoguinone~ 
diimine 
2-Chloro-1,4-phenylenediamine sulfate {24 g, 0.1 mole) 
was dissolved in water {300 mL). Hypobromite solution was 
prepared by dissolving 64 g (0.2 mole) o,f bromine in a 
I 
solution of 16 g (0.42 mole) of sodium ~ydroxide in 500 mL 
of water. To half the hypobromite solution, half the ---"' 
cooled amine solution was added with stirring. The re-
maining amine solution was similarly oxidized. The 
resulting yellow precipitate was filtered out, washed with 
water and dried under vacuum. The crude product was 
recrystallized from absolute ethanol. The yield was 14.0 
g; mp 77-78°0. The theoretical yield was 26.2 g. The 
melting point for this compound has not been reported. 
Preparation of 2-methoxy-N,N'-dichloro~ 
1,4-benzoguinonediimine 
2-Methoxy-1,4-phenylenediamine sulfate (12.1 g, 0.05 
mole) was dissolved in 300 mL of water. A pint bottle-
of commercial bleach was stirred with ice in a 1-liter 
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beaker. The amine-salt solution was added slowly with 
stirring to the chilled bleach solution and the resulting 
dirty yellow solid was filtered out, washed with water, 
and dried under vacuum. The crude product was recrysta-
llized from ethanol. The yield was 7.9 g; mp 90°0. The 
theoretical yield was 10.25 g. The melting point for this 
compound has not been published. 
Oxidation of 1,4-phenylendiamine-2-
sulfonic acid by sodium hypobromite 
solution 
... 1,.4-Phenylenediamine-2-sulfonic ac,id {9.4g, 0;.05 mole) 
was 'dissolved in 75 mL of water. Bromine (32 g, 0.2 mole) 
was dissolved in a solution of 8 g (0.2 mole) of sodium 
hydroxide in 45 mL of water. The amine solution was added 
slowly with stirring to the chilled hypobromite solution. 
Sodium chloride (30 g) wasadded to the yellow-colored 
reaction mixture and cooled in the refrigerator overnight. 
The result~g_:solid was filtered out, washed with water and 
dried under vaccum and the crude sodium N,N'-dibromo-1,4· 
benzoquinonediimine-2-sulfonic acid was recrystalliz<ed 
from ethan61. The yield was 4.5_ g; mp 254 ... 456°C. The 
theoretical yield.was 18.3 g. No published melting ]plOint 
for thl.s c:b..mpoimd 1s available in the literature. 
Preparation of 2-nitro-N,N'-dichloro-
1,4-benzoguinonediimine34 
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Calcium hypochlorite (25g, 0.17 mole) was dissolved 
in a 300 mL round-bottomed flask. Sodium carbonate (13.5 
g, 0.17 mole) and 3.5 g (0.089 mole) of sodium hydroxide 
were dissolved in 25 mL of water. This solution was 
added to the calcium hypochlorite solution and the mixture 
shaken for 15 minutes. The filtrate was separated from 
the milky white solid by filtration, the filter cake 
·washed with and the washings added to the filtrate. The · 
combined filtrate was used as oxidizing agent rather than 
I 
Clorox, because the volume could be kept low and the 
I 
concentration was sufficient to effect the oxidation of 
2-nitro-1,4-phenylenediamine in spite of the presence of 
the deactivating nitro group. The hypochlorite solution 
was stirred with ice in a 1-liter beaker. 2-Nitro-1,4-
phenylenediamine (7 .65 g,· 0.05 mole) was dissolved in 
. 300 mL of .water. ''The amine solution was added slbwly"'w:tth 
stirring to the. chilled hypochlorite . solutio.n •. -The 
reslllting bro.wn solution.was .!iltel,"~d. out, washed· with-
water and dried under vaccum. The crude<product was re-
crys~allized from ethanol. The yield was 9.2 ~H ~P 25o0 o. 
The theoretical yield was 11 .o g. The mel:ting point :tdr . 
this ~Q~~ound has not been reported. 
Preparation of 2-nitro-N,N'-dibromobenzo-
guinonediimine 
23 
2-Nitro-1,4-phenylenediamine (7.7 g, 0.058 mole) was 
dissolved in 75 mL of water. Bromine (32g, 0.2 mole) was 
added to a solution of 8 g (0.2 mole) of sodium hydroxide 
in 250 mL of water. The amine solution was added slowly 
and with stirring to the chilled hypobromite solution. 
The resulting brown precipitate was filtered, washed with 
water and dried under vacuum. The crude product was re-
crystallized from ethanol. The yield was 7.9 g; mp 360°0. 
The theoretical yield was 17.81 g. The melting point for 
this compound has not been reported. 
Preparation of 2-chloro-N,N'-dichloro-
1, 4-benzoguinonediimine 
2-Chloro-1,4-phenylendiamine (2.5 g, 0.1 mole) was 
dissolved in 600 mL of water. One liter of commercial 
bleach was stirred with ice in a 2-liter beaker. The amine 
solution was slowly added with stirring to the chilled 
bleachsolution. The yellow solid was filtered out, dried 
and recrystallized from ethanol. The yield was 14 g; the 
theoretical yield was 20.9 g; mp 69-70°0. Ota42! reports 
that the melting point was indefinite and attributes this 
to polymerization. 
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Elemental Analysis of Compounds 
.• ' ~ ... - . --J;.,. All. the compounds were submitted to M-H-W 
Laboratories, P.O. Box 15853, Phoenix, AZ.85018 for 
elemental analysis. The results are summarized in Table 
IV. 
Spectral Analysis of Compounds 
The NMR spectra were recorded on an XL-100 (15)·NMR 
spectrometer made by Varian Associates, Palo Alto, 
California. All 1H.spectra were recorded in 5-mm samples 
at 100.1 Mhz and at 2.35 Tesla. The Pulsed Fourier 
Transformation accessory for pulsed experiments was a 
Nicolet TT-100 unit. Tetramethylsilane (TMS) was used as 
the internal standard and CDC13 was the solvent unless 
otherwise specified. The complete spectra are presented 
in Figures 2-16. Only continuous wave spectra were taken 
while using solvents other than CDC13• 
Infrared spectra of the compounds were obtained from 
·potassium bromide pellets on a Beckman IR-5A spectro-
photometer with sodium chloride optics. The complete 
spectra are presented in Figures 17-26 and major absorption 
bands are listed in Table v. The infrared spectra of all 
ten compounds have two absorption peaks in common which 
were used as evidence for the quinonoid structure. One 
peak is a medium to strong and broad band in the region 
of between 1575 and 1640 cm-1 . and the other is a relativ"ely 
weak but sharp peak at 1410-1450 cm-1• Comparison of a 
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TABLE IV 
ANALY:SIS OF COMPOUNDS FOR NITROGEN 
X 
/N N 
/y 
y 
Com:Qound No. y X 
Nitrogen 
Calcd. 1 % Found 1 % 
1 Cl H 16.00 1'5 .86 
2 Cl Cl 13.37 13.28 
3 Cl CH3 14.81 14.81 
4 Cl OCH3 13.66 13.32 
5 . Cl N02 19.09 21.69 
7 Br H 10.61 9.58 
8 Br Cl 9.38 8.92 
9 Br CH3 9.52 8.62 
10 Br OCH3 10.07 8.79 
1 1 Br N02 13.59 12.78 
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TABLE V 
INFRARED SPECTRAL ASSIGNMENTS 
FOR THE TITLE COMPOUIDS 
/N I 
y 
C=C C=N 
Stretching1 em -1 Stretching1 
1595 1448 
1595 1410 
1595 1420 
1590 1410 
1640 1450 
51 
em 
~1 
------------------------------------~---------------------Br ·H 1595 1440 
Cl 1600 1452 
CH3 1575 1420 
OCH3- 1575 1405 
N02 1615 1425 
,,.,~, 
-
~-· .... ·-- .. --- __ ... _ ...... -. ·- ~-,.-- ...... ~.--~·· -~" ....... _~ 
52 
. published IR spectrum.of benzoquinone-:1,4-diimine~4·and · 
that of N,N'-dicyclohexyl-2,5-dimethyl-1,4-benzoquinone-
diimine48 suggests that these should be attributed to 0=0 
stretching and O=N stretching modes respectively. The 
absence of bands characteristic of aromatic structure at 
1600-2000 cm-1 and 667-1200 cm-1 lend credence to the fact 
that these compounds are, in fact, quinonoid. 
The interpretations of NMR spectra were complicated 
by the lack of suitable solvents for these compounds. In 
order to have a uniform basis for the comparison of all 
the compounds, pulsed spectra were obtained in 98.5% 
0:0013 regardless of the solubility of t~e compounds. For 
those compounds that were insoluble in CDC13 and/or that 
were int.erfered with by the absorption due to the · ~· · ·:,;~ 
undeuterated solvent, NMR spectra were taken using 0014 or 
acetone-£6 as solvents. In the case of unsubstituted 
compounds, A2B2-type spectra are observed. For example, 
in the spectrum of N,N'-dichlorobenzoquinone-1,4-diimine, 
Figure 2, two triplets are observed, the chemical shifts 
being 7.1S and 7.66. The three doublets centered around 
7.16 represent the c-2 and o-6 protons being coupled with 
C-3 and C-5 protons plus the effect of s,yn ... anti isomerism. 
The mirror-image, doublets centered· a:i:ound 7. 6 S are due t&~' 
the c3 and o5 protons. The coupling constants are JAA' 
= 8.-5 cps, JBB' = 11.5 cps, JAB' = JArB = 2-.0 or 1.0 cps 
..... i. 
and JAB= JA'B' = 2.0 or 1.0 cps. N,N'-Dibromo-1,4-benzo-
quinonediimine, Figure 12 gave an identical splitting 
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pattern. 
In the case of 2-substituted compounds, a complex 
pattern is observed which can be construed as due to an 
ABX system. The proton on C-3 has a chemical shift 
different than that of C-5 and C-6 protons. Typically, 
this consists of 15 linea, 2 quartets (that sometime 
overlap) for c5 and c6 protons, from lines for C-3 proton 
and three weak combination lines. This pattern is 
considerably simplified for the nitro- and chloro-,:: . -
substituted compounds. Thus, the NMR spectra are consis-
tent with the quinonoid structure :for these compounds. 
Biological Studies 
Toxicity Studies 
It is.imperative to determine the acute host toxicity 
of a compound before its anti tumor potential can be , · 
evaluated. LD50 , the dose required to kill one-half the 
test animals within four days, serves as a good indicator 
.of the toxicity of the compound to the host animal. 
The protocol to determine LD50 consists of administer-
ing a compound intraperitoneally (i.p.) at a given dose 
level to a set of six mice weighing between 17 and 20 g 
and recording the number of deaths every 24 hrs. The 
solutions were prepared fresh by weighing a given amount 
of the compound and adding to it the necessary amount of 
salt to make it biologically isotonic. The mixture was 
ground to a very fine powder and suspended in a proper 
amount of distilled water. Appropriate volume of the 
suspension were then administered to the mice. Weights 
54 
of the mice were recorded on the day of administration of 
the compound and on the fourth day (72 hrs after the i.p. 
injection). Significant weight losses and/or excessive 
mortalities would indicate a trial at a lower dose level, 
while higher dose levels would be warranted by the absences 
of weight losses and/or deaths. The experiment is repeated 
at varying dose levels until a value for LD50 is found. 
The LD50 of each compound is given in Table VI 
expressed in terms of mg/kg of mouse as well as millimoles/ 
kg of mouse. 
Inhibition of Ascitic Sarcoma 180 
Ascitic Sarcoma 180 cells used in this study were 
originally obtained from Frederick A. French of Mt. Zion 
Hospital, San Francisco, California, through living mice 
carriers. These were maintained by transplanting 1 x 106 
cells to 4 healthy mice each week. 
Tumor cells to be used in inoculations were obtained 
by sacrificing one of the carrier mice with one-week-old 
tumor cells. The skin from the abdominal area of the 
mouse was removed and approximately 1 ml of the ascitic 
fluid was withdrawn Using 1-ml disposable syringe with a 
25-gauge needle and diluted with 20 ml of biologically 
isotonic saline solution. The number ot viable sarcoma 
X 
H 
Cl 
Me 
MeO 
N02 
so3Na 
H 
Cl 
Me 
MeO 
N02 
so3Na 
TABLE VI 
ACUTE HOST TOXICITIES OF 2-Substituted-
N,N'-DIHALOBENZOQUINONE-1,4-DIIMINES 
t I N ... y-
55 
LD50 ~mmoles7kgJ y LD50{mg7kgJ Molecular Weight 
Cl 175 176.0 0.99 
Cl 47 210.5 0.22 
Cl 245 190.0 1. 29 
Cl 75 206.0 0.36 
Cl 280 221.0 1.27 
Cl 400 255.1 1.57 
Br 200 265.0 0.75 
Br 150 295.5 0.51 
Br 380 279.0 1. 36 
Br 175 295.0 0.59 
Br 180 310.0 0.58 
Br 700 324.1 2.16 
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cells was determined using a hemocytometer after staining 
a sample of the ascitic fluid with tryphan blue dye. 
The dead cells were stained blue and ignored in the 
counting procedure. After the fluid had been diluted with 
a calculated amount of saline solution, 0.2 ml of the 
fluid containing a ca. 1 x 106 sarcoma 180 cells were 
injec~ed intraperitoneally into a set of control and test 
animals each containing six female Swiss mice weighing 
between 17 and 20 g. The day the tumor cells were implan-
ted is designated day o. 
On days 1, 2 and 3, the test animals were injected 
with a dose of the test compound and thy control animals 
with isotonic saline solution. The initial dose levels 
I 
were approximately one-third the LD50 for a single 
injection. The test suspensions were prepared fresh in a 
manner analogous to that described in the section dealing · 
with toxicity studies. Weights of the mice were taken on 
day 0 and on day 4. The animals were observed for a period 
of sixty days and any deaths duly recorded. Any mice 
surviving the .sixty-day period were considered cured if 
an autopsy failed to reveal any evidence for the presence 
of tumor cells. 
Mean survival times for the treated and the cont~ol 
animals were computed by averaging the survival times of 
the corresponding six animals. The effectiveness of a 
compound at a given dose level in inhibiting the growth of 
the sarcoma 180 tumor system is expressed as the ratio of 
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the mean survival time of the treated animals and that of 
the control animals, T/C. A T/C value of at least .125% 
is necessary for the effectiveness to be statistically 
significant. Values lower than 100% indicate acute 
chemical toxicity. 
Percent increase in life span values (ILS) can be 
computed by subtracting 100 from the % T/C values. Dose 
response curves were computed by plotting % ILS versus 
dosage. These were subjected to linear least squares 
analysis and dosage values for effecting 25% and 50% ILS 
were estimated and are designated ED25 and ED 50 . -· . "!!'P"'"; 
respectively. Biological data are summarized in Table VII. 
Optimum dose is the dose at which maximum T/C was observed. 
Therapeutic Index (TI) is the ratio of LD50 and ED25 • 
Stability Studies 
Relative stabilities for the compounds in aqueous 
solution w.ere determined spectrophotometrically. A buffer 
solution was prepared by dissolving 1.21 g (0.01 mole) of 
2-amino-2-(hydroxymethyl)-1,3-propanediol (Tria) in dis-
tilled water contained in 1-liter volumetric flask. Enough 
concentrated hydrochloric acid and distilled water were 
added to bring the pH to 7.0 and the volume to 1 liter. 
A small amount of the compound was dissolved in a 
drop of absolute ethanol and diluted with enough Tria 
buffer to obtain a ultraviolet spectrum. The instrument 
was a Cary-14 uv spectrophotometer. The cuvettes were 
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TABLE VII 
INHIBITION OF ASCITIC SARCOMA 180 
~ 
/N N/ 
y· 
.~En~e· Maxi-mum Optimum :,ii: y X T/C Dose mg/kg' TI 
msLks 
Cl H 2.25 20 7.81 9.89 22.44 
Cl Cl 2.43 15 6.03 7.6 7.79 
Cl CH d 3 3.09 60 44.74r 46.58 5.48 
Cl OCH3 1.83 20 5.01 I 9.17 14.97 
Cl NO e 2 1. 66 50 38.24 44.91 7.32 
Cl so3H 1.77 100 86.69 92.99 4.61 
Br H 1.69 25 18.47 21.94 10.83 
Br Cla 2.59 40 13.45 17.01 11.15 
Br CH3 1.54 125 108.16 122.17 3.51 
Br OCH b 3 1. 45 70 65.97 71.92 .7.65 
Br NO c 2 2.58 45 20.31 22.40 8.86 
Br so3H 1.36 250 195.15. 268.92 3.59 
a. 1 cure each at 40 and 20 mg/kg 
b. 1 cure at 70 mg/kg 
c. 1 cure each at 45, 35 and 25 mg/kg 
d. 2 cures at 60 mg/kg 
e. 1 cure each at 50 and 40 mg/kg 
1 em in thickness. Optical densities were measured at 
appropriate time intervals to provide sufficient data to 
determine the half-life period of the quinonediimines 
under hydrolytic conditions. The solutions were main-
tained in t;1. .constant temperature bath·at 24.8+0.1°C. 
Treatment of Kinetic Data 
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A first order reaction, A ·products, can be descibed 
by the equation 
o( 
i = (5) 
where o<1 is the fraction of reaction at time ti and k is 
the rate constant.o<.i is defined in tertlts of the concen-
tration of the reactant by 
= (6) 
where (Ai) and (A0 ] are concentrations of A at times ti 
and 0 respectively. Then~i ranges fromo<i=O when t=O to 
~Xi= 1 where t= oc (assuming A =0) • Because of the dimension-
less ·nature of DC i, the concentration terms can be replaced 
by some measurable physical property, in this instance, 
optical density, · OD. 
(7) 
where C is constant and the modulus signs recognize the 
fact that OD may increase or decrease with time. Express-
ing~ in terms of OD gives 
(a) 
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and, combining equations (5) and (8) and taking logarithms 
(9) 
The rate constants can then be determined from the measured 
values of ODi' i=1, ••• ,n and OD~ and plotting · 
ln (IODi- OD~\) against ti without the need to know OD0 • 
However, an accurate measurement of 0~ is not always 
possible because of one or more of the following: preci-
pitation, further reaction of the products at long times 
and the desirability of an estimate of the rate constant 
before the completion of an especially slow reaction. 
While several methods are available for the estimation of 
OD« and discussed. by Holt and Norris30 , 'the direct search 
algorithm of Davies, Swann, and Campey1, is used because 
of its simplicity and speed of convergence. The Fortran 
program was kindly supplied by Holt and Norris and was 
utilized slightly modified. 
The results of the above search are summarized in 
Tables VIII-XV. The rate constant thus obtained, k, is· 
used to estimate the half-life period, ti, which is given by 
= 0.693/k ( 1-0) 
The half-life periods are listed in Table XVI. 
Structure-Activity Relationship Studies 
Hansch Correlations 
Numerical values for substituent constants used in 
this analysis were from the list published by Hansch and 
TABLE VIII 
THE HYDROLYSIS OF N,N'-DICHLOR0-1,4-
BENZOQUINONEDIIMINE 
Data Set 1 Analysed By Direct Search Over Infinity 
Optical Density 
Initial Stepsize = -0.0367A 
;.Minimum .Required Stepsize = 3.67 x 10-5A 
Step Sizes Are. Reduced. By 0.0500 -~~ 
Process Converged After 18 Function 
Evaluati.ons 
~ .Minimum Weighted Sum Of Squares = 0.01536279 
Final Estimates: 
First.Order Rate Constant = 0.016±0.005HR-1 
Initial Optical Density = 1 .24±0.065A .-; 
Infinity Optical Density = 0.48A 
Comparison Of Data Predicted Using Optimized Infinity 
Optical Density 
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Time T Optical Density A(T) 
HR Experimental Predicted 
Ln (A(T)-A(INF)) 
Experimental Predicted 
0.87 
2.13 
3.58 
19.7 
23.7 
31.2 
50.3 
55.6 
72.0 
1.21 
1.18 
1 .18 
1.07 
1.03 
0.979 
0.773 
0.686 
0.484 
1.22 
1.21 
1.19 
1. 03 
0.999 
0.940 
0.819 
0.791 
0.719 
-0.3091 
-0.3522 
-0.3622 
-0.5241 
-0.5904 
-0.7030 
-1.241 
-1.599 
-9.329 
·-0.2939 
-0.3143 
-0.3377 
-0.5985 
-0.6630 
-0.7844 
-1.092 
-1 .179 
-1.444 
TABLE IX 
THE HYDROLYSIS OF · 2-C.HLORO""J;j, N '· .... 
DICHLOR0-1,4-BENZOQUINONE-
DIIMINE 
Data Set 2 Analysed By Direct Search Over Infinity 
Optical Density 
Initial Stepsize = -0.0353A 
Mini~um Required Stepsize = 3.53 x 10-5A 
Step Sizez Are Reduced By 0.0500 
Process Converged After 18 Function 
Evaluations 
Minimum Weighted Sum Of Squares = 0.02589126 
Final Estimates: 
0.010±0.001HR-1 First Order Rate Constant = 
Initial Optical Density = o.009±0.041A 
Infinity Optical Density = 0.43A 
Comparison Of Data Predicted Using Optimized Infinity 
Optical Density 
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Time T Optical Density A(T) 
HR Experimental Predicted 
Ln (A(T)-A(INF)) 
Experimenal Predicted 
0.75 
'5.8 
23.1 
29.3 
43.0 
45.9 
76.0 
93.0 
119. 
1.53 
1.51 
1.45 
1.24 
1.16 
1.19 
0.939 
0.815 
0.830 
1. 57 . 
1.52 
1.34 
1.29 
1 .18 
1.16 
0.976 
0.892 
0.786 
0.0974 
0.0782 
0.0212 
-0.2102 
-0.3087 
-0.2792 
-0.6824 
-0.9639 
-0.9253 
0.1346 
0.0843 
-0.874 
-0.1484 
-0.2846 
-0.3127 
-0.6106 
-0.7797 
-1.042 
TABLE X 
THE HYDROLYSIS OF 2-METHYL-N,N'-
DICHLOR0-1,4-BENZOQUINONE-
DIIMINE 
Data Set e Analysed By Direct Search Over Infinity 
Optical Density 
Initial Stepsize = -0.0446A 
Minimum Required Stepsize = 4.46 x 10-5A 
Step Sizes Are Reduced By 0.0500 
Process Converged After 18 Function 
Evaluations 
Minimum Weighted Sumi Of Squares = ,0.0004049675 
Final Estimates: 
0.01±0.0004HR-1 First Order Rate Constant = 
Initial Optical Density = 1.38±0.006A 
Infinity Optical Density = 0.29A 
Comparison Of Data Predicted Using Optimized Infinity 
Optical Density 
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Time T Optical Density A(T) 
HR Experimental Predicted 
Ln (A(T)-A(INF)) 
Experimental Predicted 
o.o8 
2.67 
5.42 
10.5 
27.5 
94.6 
1. 39 
1. 31 
1.28 
1.19 
0.968 
0.498 
1.37 
1.33 
1.28 
1.19 
0.963 
0.498 
0.0919 
0.0240 
-0.0046 
-0.1094 
-0.3939 
-1.5877 
0.0827 
0.0372 
-0.0113 
-0.1009 
-0.4006 
-1.585 
TABLE XI 
THE HYDROLYSIS OF 2-METHOXY-N,N'-
DICHLOR0-1,4-BENZOQUINONE-
DIIMINE 
Data Set 4 Analysed By Direct Search Over Infinity 
Optical Density 
Initial Stepsize = -0.0133A 
Minimum Required Stepsize = 1.33 x 10-5A 
Step Sizes Are Reduced By 0.0500 
Process Converged After 18 Function'n 
Evaluations 
Minimum Weighted Sum Of Squares ='0.0001293646 
Final Estimates: 
First Order Rate Constant = 0.027±0.002HR-1 
Initial Optical Density = 0.821±0.005A 
Infinity Optical Density = 0.53A 
Comparison Of Data Predicted Using Optimized Infinity 
Optical Density 
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Time T Optical Density A(T) 
HR Experimental Predicted 
Ln (A(T)-A(INF)) 
Experimental Predicted 
0.63 
2.17 
4.25 
9.83 
96.1 
0.82 
0.-79 
0.78 
0.75 
0.55 
0.81 
0.80 
0.78 
0.75 
0.55 
-1.2413 -1.2656 
-1.3394 -1.3067 
-1.3665 -1.3621 
-1.5006 -1.5109 
-3.8170 -3.8126 
TABLE XII 
THE HYDROLYSIS OF 2-MET.HOXY-N,N'-
DICHLQR0:-1,4-BENZOQUINONE-
DIIMINE 
Data Set 5 Analysed By Direct Search Over Infinity 
Optical Density 
Initial Stepsize 
Minimum Required Stepsize 
Step Sizes Are Reduced By 0.0500 
Process Converged After 18 Function 
Evaluations· 
Minimum Weighted Sum Of Squares 
= -0.0398A 
= 3.97 X 10-SA 
=·0.002162764 
I 
Final Estimates: 
First Order Rate Constant = 0.029±0.002HR-1 
Initial Optical Density = 1.49±0.03A 
Infinity Optical Density = 0.52A 
Comparison Of Data Predicted Using 
Optical Density 
Optimized Infinity 
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Time T Optical Density A(T) 
HR Experimental Predicted 
Ln (A(T)-A(INF)) 
Experimental Predicted 
;o. 75 
23.0 
47.2 
67.0 
1.47 
1. 04 
0.72 
0.67 
1.47 
1.02 
0.77 
0.66 
-0.0503 
-0.6483 
-1.5707 
-1.8585 
-0.0456. 
-0.6855 
-1.3817 
-1.9535 
TABLE XIII 
THE HYDROLYSIS OF 2-CHLORO-N,N'-
DIBROM0-1,4-BENZOQUINONE-
DIIMINE 
Data Set 6 Analysed By Direct Search Over Infinity 
Optical Density 
. Initial Stepsize = -0.0188A 
= 1.88 X 10-5A Minimum Required Stepsize 
Step Sizes Are Reduced By 0.0500 
Process Converged After 18 Function 
Evaluations 
Minimum Weighted Sum Of $quares =1 0.001751659 
Final Estimates: 
First Order Rate Constant = 0.52±0.034HR-1 
. Initial Optical Density = 1.23±0.030A 
Infinity Optical Density = 0.62A 
Comparison Of Data Predicted Using Optimized Infinity 
Optical Density 
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Time T OpticaL Density A(T) · 
HR Experimental Predicted 
Ln (A(T)-A(INF)) 
Experimental Predicted 
0.78 
0.92 
1.03 
1.72 
1.78 
1.92 
2.13 
2.20 
4.22 
1.05 
0.98 
0.95 
0.87 
0.86 
0.84 
0.82 
.0.82 
0.68 
1.02 
1.00 
0.97 
0.86 
0.86 
0.84 
0.81 
0.81 
0.68 
-0.8263 
-0.9979 
-1.1007 
-1.3758 
-1.4161 
-1.4932 
-1.5719 
-1.5963 
-2.7702 
-0.88666 
-0.96053 
-1.0186 
-1.3826 
-1.4143 
-rt .,4882 
-1.5990 
-1.6359 
-2.7017 
TABLE XIV 
THE HYDROLYSIS OF 2-METHYL-N,N'-
DIBROM0-1,4-BENZOQUINONE-
DIIMINE 
Data Set 7 Analysed By Direct Search Over Infinity 
Optical Density 
Initial Stepsize = -0.0128 
Minimum Required Stepsize = 1.28 x 1"0-5A 
Step Sizes Are Reduced By 0.0500 
Process Converged After 18 Function 
Evaluations 
Minimum Weighted Sum Of Squares = 0.0035955 
Final Estimates: 
0.027±0.011HR-1 First Order Rate Constant = 
Initial Optical Density = 0.88,±0.068A 
Infinity Optical Density = o.61A 
Comparison Of Data Predicted Using Optimized Infinity 
Optical Density 
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Time T Optical Density A(T) 
HR Experimental Predicted 
Ln (A(T)-A(INF)) 
Experimental Predicted 
0.53 
23.5 
30~3 
43.3 
48.6 
77.7 
90.9 
0.89 
0.68 
0.60 
0.70 
0.66 
0.66 
0.63 
0.88 
0.75 
0.72. 
0.69 
0.68 
0.64 
0.63 
-1.2673 
-2.6367 
-6.0325 
-2.3903 
-2.9677 
-2.9642 
-3.6651 
-1.3002 
-1.9275 
-2.1140 
-2.4701 
-2.6148 
-3.4089 
-3.7686 
TABLE XV 
THE HYDROLYSIS OF 2-METHOXY-N,N'-
DIBROM0•1,4-BENZOQUINONE-
DIIMINE 
Data Set 8 Analysed By Direct Search Over Infinity 
Optical Density 
Initial Stepsize = -0.0172A 
Minimum Required Stepsize = 1.72 x 10-5A 
Step Sizes Are Reduced By 0.0500 
Process Converged After 18 Function 
Evaluations 
Minimum Weighted Sum Of Squares = 0.02829888. 
Final Estimates: 
0.025±0.013HR-1 First Order Rate Constant = 
Initial Optical Density = 1.271±0.095A 
Infinity Optical Density = 0.92A 
Comparison Of Data Predicted Using Optimized Infinity 
Optical Density 
Time T Optical Density A(T) Ln (A(T)-A~!NR}) .. 
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HR Experimental Predicted · Experimental· P:reci.tcted 
0.75 
5.08 
19.2 
22.2 
46.2· 
68.5 
95.6 
1.32 
1.09 
1.02 
t.01 
1.01 
0.83 
0.98 
1.26 
1.22 
1.13 
1.12 
1.03 
0.98 
0.95 
-0.9057 
-1.7415 
-2.3304 
-2.3512 
-2.4162 
-2.3779 
-2.8091 
-1.0748 
-1.1822 
-1.5326 
~1.6990 
-2.2038 
-2.7578 
-3.4300 
Compound 
No. 
1 
2 
3 
TABLE XVI 
HALF-LIFE.PERIODS"OF N,N'-DIHALQ-1,4-
BENZOQUINONEDIIMINES UNDER 
HYDROLYTIC CONDITIONS 
Rate Constant;. Half-life Period 
k X 102 Hr-1 Ti, Hrs 
1.62 42.7 
0.99 69.7 
1.76 39.1 
4 ~Trial 1~ 2.67 25.9 Trial 2 2.88 24.0 
8 52.76 1.3 
9 2.7 25.3 
10 2.48 27.8 
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co-workers24. In addition, parachor values were calculated 
for all the compounds2•46 • Hydrophobic fragmental 
constants (HF) introduced by Nys and Rekker4°,41 were 
used as a measure of hydrophobicity-lipophilicity. ~he 
various constants are listed in Table XVII. 
The dependent variables used were log(1/ED25M) and. 
Tog(1/LD50M) where ED25M and LD50M are ED25 (effective 
dose, 25%) and LD50 (lethal dose, 50%), expressed in 
mmoles/kg o! mouse. 
The multiple regression was performed using the step-
wise procedure available in Statistical Analysis System 
(SAS) programs package. The program is, documented in a 
clear and usable manner50 • The statist~cal results were 
interpreted according to Draper and Smith 16 • Both the 
sulfonic acid compounds were omitted from the analysis 
because of their questionable purities. The set o! 
dependent variables offered as input to the program· 
consisted of the eight substituent parameters, their 
squared values. and all possible cross .products' of two 
variables taken at a time. 
Discriminant Ana:J.vsis 
The BMD07M Stepwise Discriminant Analysis program, 
revised December 1975, developed at the Health Sciences 
Computing Facility, University of California at: Los Angeles 
was used to perform all the discriminant analysis 
· .. - ·::. 7""'--
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TABLE XVII 
PARAMETERS USED IN HANSCH CORRELATIONS 
and discriminant analyses 
Com- ;: Ib poung 0 71" R MR MW HF PAR 
No. 
1 o.o o.o o.o o.o 1.03 175.0 ·.o.1g3 .· 332.2 0 
2 0.23 0.71 0.41 -0.15 6.03 209.4 0.930 371.9 0 
3 -0.17 . 0.56 -0.04 -0.13 5.65 189.0 0.702 372.2 0 
4 -0.27 -0.02 0.26 -0.51 7.87 205.0 0.244 392.0 0 
5 0.78 -0.28 0.67 0.16 7.36 220.0 -0.089 399.4 0 
7 o.o o.o o.o o.o 1.03 262.0 0.193 357.8 1 
8 0.23 0.71 0.41 -0.15 6.03 296.4 0.930 397.5 1 
9 -0.17 0.56 -0.04 -0.13 5.65 276.0 0.702 397.8 1 
10 -0.27 -0.02 0.26 -0.51 7.87 292.0 0.244 417.6 1 
1 1 0.78 0.28 0.67 0.16 7.36 307.0 -0.089 425.0 1 
a. Compounds are designated by the numbers assigned to 
them in Table III. 
b. Indicator·constants used to differentiate between 
functional groups (i.e.) N,N'-dichloro- and N,N'-
dibromo-1,4-benzoquinonediiminee. 
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* computations in this study • Classification functions are 
established for each group by selecting the independent 
variables one by one in a stepwise manner. The variable 
with the greatest partial F value is entered at each step. 
If the F value for a particular variable drops below a 
desired level of significance as other variables are 
added, that variable is eliminated from the classification 
function. The procedures used in this program and the 
optio~s available are clearly documented15 • Some of these 
are summarized herein: 
• • • The program first calculates and prints the 
overall mean for each variable, the group mean for 
each group, the standard deviation~ for each variable 
in each group, the within and total cross-product 
matrices, the within-group covariance matrix, and 
the within-groups correlation matrix. 
In the first step . of the stepWise·· procedure 
for selection of variables for the classification 
functions, the variable with the greatest partial 
F value is entered. This variable is the one 
that alone can best describe the difference 
between the groups. In each subsequent step, one 
variable is added or removed from the classification 
functions according to the following procedures. 
(a) If one or more variables that have 
already been entered into the classification . 
functions have an F value to remove that is smaller 
than the value set for the program (normally · 
0.005 unless modified by the user), then the 
variable with the smallest F value will be removed. (b) If no variable is removed from the 
classification. functions is chosen by one of three 
alternative procedures. We have chosen to use 
throughout this work option (1) that selects the 
variable with the greatest F value to enter. 
This variable is the one that together with the 
variables already entered in the classification 
functions provides the best discrimination 
between the groups. At each step a classification 
function is derived for each group, the compounds 
*The Health Sciences computing facility is sponsored 
by NIH special Research Resources Grant RR...;.3. 
are classified into each group based on the 
classification functions just derived, and the 
numbers of cases correctly and incorrectly 
classified are printed. 
A classification function for each group k 
of n members is calculated as 
T3 
~-
ckj = (n - g) ~ xkjaij ( 11) . 
i=1,2, ••• ,r; k=1,2, ••• ,g 
where ckj is the coefficient for variable vj of group 
k, g is the number of groups used for the analysis, 
r is the number of variables used, i and j indicate 
the variables, aij is the determinant of_ the inverse 
within-group cross-products matrix, and xkj is the 
group mean for variable j. A constant term, cko' is 
calculated for each classification function. 
( 12) 
k=1,2, ••• ,g 
For purposes of predicting the classification 
of each case (or compound), the mth classification 
function, slmk' can be evaluated for case k of 
group 1 
(13) 
where cmo is the constant term in the classification 
function for group m, cmj is the coefficient for 
var~able j in the classification function for group 
m, and xlkj is the value of variable j for case k of 
group 1. The posterior probability, Plmk' of case 
k in group 1 having come from group m can be 
calculated 
P . '' Pm exp( slmk) 1 k = , ( 14) 
m ~Pi exp(slik) 
where Pm is the prior probability of group m, Pi is 
the prior probability of group i, and slik is the 
function evaluated for case k of group i. This 
program calculates the posterior probability of each 
compound (case) belonging to each group on the basis 
of the classification functions developed in the last 
step. The stepwise procedure terminates at a 
predetermined number of steps or when no variable 
meets the criteria (F value) set for entry or 
remova143 • P• 369 • 
The substituent constants used in the discriminant 
analysis are also listed in Table XVII. The compounds 
are ranked according to their values for ED25 , LD50 
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and TD in Table XVII. The compounds were divided into 
two groups containing 5. compounds each. Group 1 with low 
values will represent active.compounds in the case of 
ED25 , toxic compounds in the case of LD50 and inactive 
compounds in the case of TI. 
Free-Wilson Additivity Correlations 
Once again, Compounds ~ and 12 were omitted from 
these correlations because of lack of purity. The fully 
constructed structural matrix used is shown in Table XIX. 
Instead of using the full matrix and applying the 
restricting conditions, the method of Cammarata10 was 
used. Unsubstituted N,N'-dichloro~1,4-benzoquinonediimine 
was considered the basic compound for the whole set. 
This means thatr inequation 4 (p.g) takes the 
value of the biological. activity for N,N'-diclioro-1,4-
benzoquinonediimine rather than represent the average 
biological activity for the whole set of compounds. 
Consequently, the constants I 1 and I 3, indicating the 
chloro atom on N and the hydrogen atom at the 2-position 
respectively, are superfluous. 
It is no longer necessary to apply the restrictive 
Group 1 
TABLE· XVIII 
RANK OF COMPOUNDS BY DIFFERENT .NDICES 
OF BIOLOGICAL ACTIVITIES 
ED25 LD50 
5 2 
4 4 
Low Values 2 8 
1 10 
TI 
9 
3 
5 
10 
8 1 2 
75 
---------------------------------------~------------------1 1 11 11 
Group 2 7 7 7 
High·Values 3 3 .a 
10 5 4 
9 9 1 
* The compounds are designated by numbers assigned to 
them in Table III 
Compound 
No. 
1 
2 
3 
4 
5 
7 
8 
9 
10 
1 1 
TABLE XIX 
FULLY CONSTRUCTED STRUCTURAL MATRIX 
USED IN THE FREE-WILSON 
ADDITIVITY MODEL 
·1. 
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-~----------Q2!E2~~g-I~!~~!~!£!~!2~----------
y : X 
---------- ---------------------------------Cl Br H Cl CH~ OCH3 N02 
1 0 1 0 0 0 0 
1 0 0 1 0 0 0 
1 0 0 0 1 0 0 
1 0 0 0 0 1 0 
1 0 0 0 0 0 1 
0 0 1 0 0 0 0 
0 0 0 1 0 0 ·o 
0 1 0 0 1 0 0 
0 1 0 0 0 1 0 
0 1 0 .0 0 0 1 
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conditions that 11 + 12 = 0 and 13 + 14 + 15 +I 6 +I7 = o. 
The resulting simplified matrix which was used in this 
study is shown Table XX. The numberical value of each 
constant indicates the contribution to the antitumor 
activity of a particular substituent at a particular 
position. These values were obtained by using the step-
wise procedure available in the Statistical Analysis 
System {SAS) programs package. 
Compound 
No. 
1 
2 
3 
4 
5 
7 
8 
10 
11 
TABLE XX 
SIMPLIFIED STRUCTURAL WATRIX USED IN 
THIS STUDY 
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____________ Q£!IDE2·1!!!Q; .. !9;~!!~!!!£!~!2!! ........................ .. 
y 
-------
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
X 
---------------------------------------
0 
1 
0 
0 
0 
0 
1 
0 
0 
0 
0 
0 
1 
0 
0 
0 
0 
1 
0 
0 
0 
0 
iO 
1 
0 
0 
0 
0 
1 
0 
0 
0 
0 
0 
1 
0 
0 
0 
0 
1 
The above matrixwas derived from the fully 
constructed matrix presented in Table XIX 
' 
CHAPTER IV 
RESULTS AND DISCUSSION 
:Biological. Studies 
The values for LD50 indicate that N,N'-dichloro-1,4-
benzoquinonediimines are more toxic than the corresponding 
bromo analogs. Chlorine atom at the 2-position imparts 
high toxicity. Consistent with the general axiom of 
coincidence of chemical toxicity with effectiveness in 
drug therapy, the dichlorodiimines are more active against 
sarcoma 180 as evidenced by their having higher T/C values, 
lower optimal doses, and lower effective doses than the 
bromo counterparts. 
The fact that the dichloro compounds have higher 
therapeutic indices than the corresponding dibromo 
compounds implies that the high activities at low dose 
levels more than compensate for their high toxicities. 
Stability Studies 
In the case of 2-methoxy-N,N'-dichloro-1,4-benzo-
quinonediimine, where two trials were conducted, the rate 
constant was reproducible within 7.8%. Among the seven 
compounds for which half-life periods in hydrolysis are 
pr-esented in Table XV, the chloro analogs are more stable 
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than the bromo compounds. It is supposed that they under-
go hydrolysis to produce the corresponding dioximes. 
Biological data available on monohaloimines and monooximes 
indicate that the former are more eff~ctive against 
ascitic sarcoma 180. This should explain the smaller 
effectiveness of dibromoimines which are less stable in 
aqueous solutions. The incompleteness of the stability 
studies preclude their inclusion in any quantitative 
structure-act! vity studies. 
Chemical Studies 
Elemental analysis and spectral data essentially 
establish the quinonoid structure of th~ compounds in 
this study. However compounds 6 and 1£, which contain 
the so3Na group, contain NaCl used to aid in their preci-
pitation. Their low toxicities and ineffectiveness 
~gainst sarcoma 180 tumor system could be caused by the 
presence of sodium chloride. Hence, these compounds 
have been excluded from all the structure activity studies. 
Hansch Correlations 
When the ten 2-substituted-N,N'-dihalo-1,4-benzo-
quinonediimines were subjected to Hansch-type multiple 
regression analysis, the indicator constant was forcibly 
included in all the correlations. When log(1/ED25M) was 
the independent variable, the following structure-actYity. 
relationship was obtained. 
8t 
log(1/ED25M) = -0.032MW + 2.842~+ 2.383I + 6.96 (15) 
(n = 10; s = 0.06; r = 0.89) 
The multiple correlation coefficient r is 0.89 and r 2 
has a value of 0.80 Which means that 80%. of the variable 
space been "explained 11 by the regression equation. The 
F value of 8.01 for the whole analysis is greater than 
standard F distribution of F3, 8 , 0 •99 = 7.59, implying that 
the correlation is significant at 99% level. Further more, 
the null hypothesis that the coefficients of~ and MW are 
zero are rejected with a confidence level of 98.77%. and 
94.62% respectively. 
This relationship would imply that fitnd ef!e>ct: and 
molecular weight play a significant role in the antitumor 
activity of these compounds. 
In the case of LD50 , the following relationship was 
obtained: 
log(1/LD50M) = 0.0019· MW:P'+ 1.4936'=11- 0.0462I + 0.0852 (16) 
(n = 10; s = 0.0232; r = 0.864) 
r 2 has a value of 0.746 meaning that 74.6% of variable 
space is explai_ned by the correlat~on; F = 5.889) F316 , 0•95 
= 4. 74. Once again the null hyp·othesis that the : · · ·· 
cofficients are· zero is rejected. 
Based on equations 15 and 16, log(1/ED25M) and .. 
log(1/LD50M) were calculated for all the ten compounds. 
Reasonable agreement between experimental and calculated 
values are found as shown in Table XXI. 
An inspection of the QSARs . suggests. ways· .. of. designing 
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TABLE XXI 
---RESULTS OF HANSOH CORRELATIONS -·A 
COMPARISON OF THE PREDICTED 
AND EXPERIMENTAL_ 
ACTIVITIES ·' 
Log (1/ED2 M) (1/LD50M) Com.:.;. Log 
pound --------~-----2------ -----------------------Exp.eri- Pr.e- Resi- · Experi- Pre- Resib No. mental dieted dual a mental dieted dual 
1 1.35 1.36 -0.01 o.o 0.09 -0.09 
2 1.54 1.42 0.12 0.65 0.49 0.16 
3 0.63 0.80 -0.17 -0.11 -0.07 -0.04 
4 1.61 1 .14 0.47 0.31 0.19 0.12 
5 1.71 1.82 -0.11 -0.10 0.04 -0.14 
7 1.15 0.96 0.19 0.12 0.04 0.08 
8 1.34 1.02 0.32 0.30 0.51 -0.21 
9 0.41 0.40 0.01 -0.14 -0.12 -0.02 
10 0.65 0.74 -0.09 0.22 0.19 0.03 
11 1. 41 1.42 -0.01 0.23 0.10 0.13 
a. Net residual = o.77; b. Net residual = 0.02 
new compounds with better antitumor activity. The increase 
of~ and MW will result in the decrease of ED25M and hence 
the increase in potency. This would decrease the value 
for LD50M as well, yielding drugs with low toxicity. 
Toxicity can also be reduced by selecting substitutents 
such that the values for 7Tand ~are numerically large but 
with opposite signs. Electron~withdrawing groups have large 
values forcr. If these are chosen so that they have large 
~, large formula weights, and high water solubility (large 
negative values for~), the resulting compounds will be 
effective and non-toxic. 
Discriminant Analysis 
Discriminant analysis was able to successfully 
classify the ten compounds into active and moderately 
active groups based on ED25 at a statistically significant 
level. ~ and molecular weight were able to classify all 
.the compounds correctly at a confidence level of 97.5% 
(F = 7.82;> F2, 7, 0 •975=6.54). 
The classification functions obtained were: 
for active compounds 
-15.33(11.47)F + 0.16(9.09)MW- 15.59 
for moderatively active compounds 
-30.05(11.47)~ + 0~24(9.09)MW- 29.93 (17) 
where the numbers in parantheses are F to enter with 
degrees of freedom being 1, 7 for-·the ~orresponding 
variables. Substituents with large values for~ should be 
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given consideration for future study. 
The following results were obtained when the benzo-
quinonediimines were divided into (a) toxic group (low 
values of LD50 ) and .(b)-.non-.toxic group (high values of 
LD50 ), each group consisting of five compounds and 
subjected to discriminant analysis. 
The classification functions were: 
for toxic compounds 
-176.7(7.50)cr+ 376.2(15.71)R + 1.93(8.02)PAR- 954 
for non-toxic compounds 
-158.3(7.50)6' + 325.6(15.71 )R + 1.73(8.02)PAR- 1149 
The analysis was significant at the 95%~ level (F = 6.26 
F3, 6 , 0 •95=4.74). All the ten compounds were classified 
correctly. Substituents with large values for Rand 
parachor and large negative values for~ will result in 
lower toxicity. 
The benzoquinonediimines were then divided into two 
groups based on their therapeutic index, five compounds 
with low values as moderatively active and five compounds 
with high values as active and subjected to discriminant 
analysis. A four variable set of ff, 1t, MR, and parachor 
classified all the ten compounds correctly. However, the 
analysis was not significant even at 75% level. 
Free-Wilson Additivity Studies 
The results of the Free-Wilson analysis depicting the 
contributions of various substituents to ED25 , LD50 and TI 
are shown in Table XXII. The constant term in each case 
would represent the activity of the unsubstituted N,N'-
dichlorobenzoquinonediimine and a comparison of these with 
the experimental values are presented in Table XXII!~ 
Nearly eighty-four percent of .l;he variation in ED25 
is explained by the additivity model as evidenced by the 
value of 0.915 for the multiple correlation coefficient r, 
the value of r 2being 0.838. The analysis is significant 
at the 90 percent level, for F = 4.14) F5, 4, 0•90=4.05. 
The additivity model explains seventy-eight percent 
of the variations in LD50 , since r = 0.885 and r 2 = 0.783. 
The analysis is significant at the 84 percent level, since 
I 
F = 2.89) F5, 4, 0•75=2.07. 
Only seventy-one percent of the variations in TI 
are explained by this model because r = 0.843 and r 2 = 0.71. 
The analysis is significant at 74 percent level, because 
F = .1.97~F5 , 4 , 0 • 75 = 2.07. 
The effect of replacing the chloro atoms at N and Nt 
posi tiona by bromo atoms is indicated by the values of,"' the 
~ E£!2 constant I 1 in Table XXII. The substit~tion adds 
to the effective and toxic dosages but lowers the thera-
peutic index. The advantage of low toxicities of the 
dibromo compounds is offset by the larger doses needed 
for antitumor activities. The nitro substituent is the 
most effective, but confers some toxicity. The chloro 
atom -is the most toxic and the second most effective next 
only to the nitro group. The therapeutic index results 
TABLE XXII 
CONTRIBUTION OF STRUCTURAL CHANGES TO 
BIOLOGICAL ACTIVITIES 
Position Substituent Constant . Contribution to 
.. ED 25 LD50 TI 
x Br I 1 30.04 ' 47.6 -15.44 
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-----------------------------------------------------------y Cl I2 -3.40 ·-89.0 -7.16 
CH3 I3 63.34 125.0 -12.14 
. OCH3 I . 4 22.36 -50.0 -5.33 
N02 I5 -4.96 42.5 23.18 
TABLE XXIll 
COMPARISON OF PREDICTED AND EXPERIMENTAL 
BIOLOGICAL ACTIVITIES OF N,N'-Di-
CHLOR0-1,4-BENZOQUINONEDIIMINE 
Biological Predicted Experimental Activity 
ED25 
-1.89 7.81 
LD50 163.7 175.0 
,. 
TI 24.35 22.44 
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suggest, however, that the nitro group is the most 
effective. 
Recommendations for Future Study 
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Nitrogen analogues of naphthoquinones and anthra-
quinones should be synthesized and their biological 
potential should be evaluated. A series of 4-substituted-
N,N'-dihalo-1,2-benzoquinonediimines should also be 
examined for their antitumor activity. Discriminant 
analysis should be applied to the volume of antitumor data 
available in the literature with a view to test its 
reliability as a qualitative structure activity relation-
ship. 
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APPENDIX 
SYNTHESIS OF RELATED COMPOUNDS 
Preparation of 1,4-Naphthoquin0ne Dioxime 
In a 250-mL beaker, 5 g (0.032 mole) of 1,4-naphtho-
quinone (practical), 6 g (0.09 mole) of hydroxylamine 
hydrochloride and 200 mL of 95% ethanol were stirred for 
24 hrs. The reaction mixture was poured into a mixture 
of ice and water. The crude precipitate formed was 
filtered out and recrystallized from ethanol-water mixture. 
The yield was 2.7 g. The theoretical yield was 6.02 g. 
mp 204-205°C dec. Published: 207°c39. 
Preparation of 2,3-Dibromo-1,4-naphtho-
quinone Dioxime 
1,4-Naphthoquinone dioxime (2 g, 0.01 mole) was 
dissolved in 30 mL of glacial acetic acid. This solution 
was cooled to room temperature and 2 g (0.013 mole) of 
bromine was added. The reaction mixture was stirred over-
night and poured into ice-water mixture. The resultin~ 
red-brown precipitate was filtered out, washed with water 
and recrystallized from ethanol water mixture. The yield 
was 1.8 g. mp 195°0. The theoretical yield was 3.46 g. 
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The melting point for this compound has not been repor~ed. 
Oxidation of 1,2-Phenylenediamine 
by Hypobromite 
In a 1-liter beaker, 5.4 g (0~05 mole) of 1,2- <;r~-·-· 
phenylenediamine was dissolved in 300 mL of water. 
Bromine (32 g, 0.2 mole) was dissolved in a solution of 
16.7 g (0.4 mole) of sodium hydroxide in 500 mL of water 
and stirred with ice. To the chilled hydrobromite 
.solution was added the amine solution slowly and with 
stirring. The precipitate formed was dried under vacuum. 
It was recrystallized from ethanol. The yield was 7 g. 
mp 250°C. The theoretical yield was 13.2 g. No melting 
point has been reported for this compound. 
Oxidation of 1,2-Phenylenediamine 
by Bleach 
In a 500 mL beaker, 5.4 g (0.05 mole) of 1 ,2-.. · w.-._.?-n: 
phenylenediamine was dissolved in 300 mL of water was 
added to 500 mL of commercial bleach chilled in a 1-liter 
beaker slowly and with stirring. The resultant yellow 
precipitate was filtered, washed with water and dried 
under vacuum. The crude N,N'-dichloro-1,2-benzoquinone-
diimine was recrystallized from ethanol. The yield was 
6.2 g. The theoretical yield was 8.75 g. mp 250°C. The 
melting point for this compound has not been reported. 
Oxidation of 4-Chloro-1,2-phenylene-
diamine 
4-Chloro-1,2-phenylenediamine (7.2 g, 0.05 mole) was 
dissolved in 300 mL of water in a 500 mL beaker. To a 
chilled commercial bleach solution (500 mL) was added 
the amine solution slowly and with stirring. The resulting 
precipitate was filtered, washed with water and dried 
under vacuum. The crude product was recrystallized from 
ethanol. The yield was 6.9 g. The theoretical yield was 
10.48 g. mp 250°C. The melting point for this compound 
has not been published~ 
VITA 
Gopalakri·shnan Prakash 
Candidate for the Degree of 
Doctor of Philosophy 
Thesis: METHODS. OF DRUG DESIGN APPLIED TO .. BENZOQUINONE 
ANALOGUES AND THEIR ACTIVITIES AGAINST ASCITIC 
SARCOMA 180 IN SWISS MICE 
Major Field: Chemistry 
Biographical: 
Personal Data: Born in Thiruvadanai, India, June 15, 
1951, the son of Mr. and Mrs •. M. s. Gopalakrishna. 
Education: Graduated from Sri Ramakrishna Vidyasala 
High School, Chidambaram, India, in April, 1966; 
received the Bachelor of Science degree from 
Annamalai University, India in May, 1970; comple-
ted requirements for the Doctor of Philosophy 
degree at Oklahoma State University in December, 
1979. 
Professional Experience: National Hindi Merit 
Scholar (Government of India), Annamalai Univer-
sity, India 1966070; Graduate Teaching Assistant, 
Oklahoma State University (January 1971-July, 
1979); Monsanto Grant, Research Fellowship, 
Summer of 1971; Gulf Summer Fellow, Summer of 
1974; Sunoco Summer Fellow, Summer of 1975; 
Conoco Summer Fellow, Summer of 1976. 
Membership in Honorary and Prefessional Societies: 
Member of Phi Lambda Upsilon Honorary Chemical 
Society; Member.of American Chemical Society; 
Member of Division of Medicinal Chemistr.y, 
American Chemical Society; Member of Sigma Xi, 
the Scientific Research Society of North · 
America. 
